He Guijun, Yao Wenfeng, Li Liang, Wu Yang, Feng Guojian, Chen Li
Department of Otolaryngology and Head and Neck Surgery, Lianyungang Second People's Hospital, Lianyungang, 222023 Jiangsu China.
Department of Otolaryngology, The First People's Hospital of Xinxiang City, Xinxiang, 453000 Henan China.
Cancer Cell Int. 2020 Oct 13;20:504. doi: 10.1186/s12935-020-01565-5. eCollection 2020.
LOXL1-AS1 is a long non-coding RNA (lncRNA) that plays crucial roles in various cancers. However, the functional role of LOXL1-AS1 in laryngocarcinoma remains unclear. Thus we planned to probe into the function and underlying mechanism of LOXL1-AS1 in laryngocarcinoma.
Gene expression was evaluated in laryngocarcinoma cells using RT-qPCR. The ability of cell proliferation and migration was assessed by CCK8, colony formation, wound healing and transwell assays. The interaction among LOXL1-AS1, miR-589-5p and TRAF6 was detected by Ago2-RIP, RNA pull down and luciferase reporter assays.
LOXL1-AS1 was overexpressed in laryngocarcinoma cells. Silencing of LOXL1-AS1 suppressed cell proliferation, migration and EMT in laryngocarcinoma. Moreover, miR-589-5p, the downstream of LOXL1-AS1, directly targeted TRAF6 in laryngocarcinoma. Importantly, LOXL1-AS1 augmented TRAF6 expression in laryngocarcinoma cells by sequestering miR-589-5p. Besides, miR-589-5p worked as a tumor-inhibitor while TRAF6 functioned as a tumor-facilitator in laryngocarcinoma. Of note, rescue experiments both in vitro and in vivo validated that LOXL1-AS1 aggravated the malignancy in laryngocarcinoma by targeting miR-589-5p/TRAF6 pathway.
LOXL1-AS1 promotes the proliferation and migration of laryngocarcinoma cells through absorbing miR-589-5p to upregulate TRAF6 expression.
LOXL1-AS1是一种长链非编码RNA（lncRNA），在多种癌症中发挥关键作用。然而，LOXL1-AS1在喉癌中的功能作用仍不清楚。因此，我们计划探究LOXL1-AS1在喉癌中的功能及潜在机制。
使用RT-qPCR评估喉癌细胞中的基因表达。通过CCK8、集落形成、伤口愈合和Transwell实验评估细胞增殖和迁移能力。通过AGO2-RIP、RNA下拉和荧光素酶报告实验检测LOXL1-AS1、miR-589-5p和TRAF6之间的相互作用。
LOXL1-AS1在喉癌细胞中过表达。沉默LOXL1-AS1可抑制喉癌细胞的增殖、迁移和上皮-间质转化。此外，LOXL1-AS1的下游miR-589-5p在喉癌中直接靶向TRAF6。重要的是，LOXL1-AS1通过隔离miR-589-5p增强喉癌细胞中TRAF6的表达。此外，miR-589-5p在喉癌中起肿瘤抑制作用，而TRAF6起肿瘤促进作用。值得注意的是，体外和体内的挽救实验证实，LOXL1-AS1通过靶向miR-589-5p/TRAF6途径加重喉癌的恶性程度。
LOXL1-AS1通过吸收miR-589-5p上调TRAF6表达，促进喉癌细胞的增殖和迁移。
